“产品要有FIC/BIC潜质的药物靶点,能解决未获满足的重大临床疾病需求,这是摆脱未来竞争红海的选择,也是国内创新药企走向世界的重要基础。”编者按:自2015年中国实施新药审评审批制度改革,过去十年堪称中国医药史上变革最为迅猛的十年。这一场意义深远的变革,如同一股强劲东风,彻底重塑了中国医药行业的格局。站在药审改革十周年的关键节点上,时代财经推出“药审改革十年十人”特别报道,旨在聚焦这10年来推动...
Source Link“产品要有FIC/BIC潜质的药物靶点,能解决未获满足的重大临床疾病需求,这是摆脱未来竞争红海的选择,也是国内创新药企走向世界的重要基础。”编者按:自2015年中国实施新药审评审批制度改革,过去十年堪称中国医药史上变革最为迅猛的十年。这一场意义深远的变革,如同一股强劲东风,彻底重塑了中国医药行业的格局。站在药审改革十周年的关键节点上,时代财经推出“药审改革十年十人”特别报道,旨在聚焦这10年来推动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.